-
News | 2023.10.02
Malaria: progress towards the use of monoclonal antibodies
Although monoclonal antibodies seem to be a promising avenue for malaria prevention, their mechanism of action remains unclear. Scientists at the Institut Pasteur recently developed a model to study and identify more effective monoclonal antibodies.
-
Document de presse | 2023.10.03
The Institut Pasteur & the University of Tokyo have signed a LOI to establish the Planetary Health Innovation Center, marking the first step towards the Institut Pasteur of Japan
At a ceremony in Tokyo on Tuesday October 3, 2023 attended by the French Ambassador to Japan, H.E. Philippe Setton, the President of the Institut Pasteur, Professor Stewart Cole, and the President and Rector of the University of Tokyo, Professor Teruo Fujii, signed a letter of intent (LOI) to establish the Planetary Health Innovation Center (PHIC), marking the first step towards the Institut...
-
News | 2023.09.29
Foodborne botulism: report on the recent outbreak
In early September 2023, several people were infected after eating home-canned sardines in a bar in Bordeaux. By September 14, 2023, the outbreak had led to the death of one person, and 10 others had been admitted to hospital. Here is a detailed timeline of events and the Institut Pasteur's role in managing this health crisis.
-
News | 2023.04.25
Malaria: improving blood filtration by the spleen to stop the disease transmission
Malaria is a disease transmitted to humans by a mosquito bite, itself infected with a parasite. This parasite settles in the liver, then infects the red blood cells and destroys them. A Université Paris Cité - Inserm team, led by Prof. Pierre Buffet, Medical Vice-President of the Institut Pasteur, identifies two drugs likely to increase the efficiency of blood filtration by the spleen. This can...
-
News | 2025.02.10
The Institut Pasteur and AlterDiag announce the signature of a strategic partnership on research and development of next generation rapid diagnostic technologies
Through this long-term strategic partnership agreement, the Institut Pasteur and AlterDiag will carry out research and development projects to develop new single-domain antibodies (VHH) -based rapid diagnostic tests using lateral flow immunochromatography, with the aim of strengthening the fight against infectious diseases. Scientific and technological collaboration to meet global health...
-
Document de presse | 2020.07.15
Type 1 Interferon deficiency: A blood based Signature for Detecting Patients at risk of severe Covid-19 for a therapeutic approach
Which patients will develop a severe form of Covid-19? This is a key question that needs to be answered to improve the individual management and prognosis of patients. In a study published in Science on July 13, teams from AP-HP, Inserm, Université of Paris, Institut Pasteur and Institut Imagine describe a unique and unexpected immunological phenotype in severe and critical patients, consisting...
-
Article | 2019.08.06
Vaccinology and Immunotherapy Initiative: Innovation – Vaccine Candidates
The Institut Pasteur has a distinguished history of vaccine development as a means to improve global health. A stronghold of the Institut Pasteur in vaccines is the development of novel technologies for vaccine design and delivery with several candidates currently under clinical evaluation, either licensed to development and commercialization partners or under Institut Pasteur sponsorship.
-
Document de presse | 2016.08.29
Alzheimer's: nicotinic receptors as a new therapeutic target
Several scientific studies have indicated that nicotine may be beneficial for memory function. Scientists from the Institut Pasteur and the CNRS set out to shed further light on the properties attributed to nicotine – which is known to have an adverse effect on health – by determining the precise structure of the nicotinic receptors in the hippocampus region of the brain. Using mouse...
-
Document de presse | 2015.12.21
The mechanism of an AIDS vaccine candidate filmed in vivo
Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. This previously unseen footage clearly shows how the vaccine recruits the immune cells needed to destroy infected cells. These results, published in the...
-
Document de presse | 2014.08.27
Potential strategies for limiting the hepatitis C epidemic in Egypt
In the fight against hepatitis C, directing preventive and curative interventions towards sufferers of chronic diseases requiring regular medical care would be an effective means of reducing transmission of the hepatitis C virus (HCV) in Egypt, and undoubtedly also in other countries with limited resources. This theory has arisen from a mathematical modeling study carried out as part of the ANRS...